Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Adherium Ltd. ( (AU:ADR) ) has shared an announcement.
Adherium Limited has reported significant growth in its US commercial patient base, with a more than 100% increase in the last quarter, reaffirming its target of 9,000 remote patient monitoring patients by the end of 2025. The company has expanded its US commercialization team and released a new Hailie Smartinhaler product compatible with AstraZeneca’s AIRSUPRA and Breztri Aerosphere, enhancing its market position and offering significant opportunities for growth. Strategic partnerships with Group Purchasing Organizations and other healthcare providers are expected to streamline adoption and drive further expansion, while the integration of AI-driven algorithms aims to improve patient adherence and care management.
More about Adherium Ltd.
Adherium Limited is a leading digital health company specializing in integrated digital health solutions and connected respiratory medical devices. The company focuses on remote patient monitoring and improving respiratory care management through its Hailie Smartinhaler platform, targeting patients with conditions like COPD and asthma.
Average Trading Volume: 1,124,980
Technical Sentiment Signal: Buy
Current Market Cap: A$6.82M
Learn more about ADR stock on TipRanks’ Stock Analysis page.